✉news HealthMedicine first seen 4 d ago, last 3 d ago, peak #3
EMA recommends authorising Rasonque for metastatic pancreatic cancer
Original: EMA recommends authorisation of Rasonque for metastatic pancreatic cancer
The European Medicines Agency has recommended authorising Rasonque, a new treatment for metastatic pancreatic cancer, one of the hardest-to-treat forms of cancer with very limited existing options. The recommendation means the drug could soon become available to patients across the European Union once the European Commission grants final approval. Medical communities have welcomed the news given the poor prognosis typically associated with advanced pancreatic cancer.
Why now: A new medicine for one of the deadliest cancers is a major regulatory milestone, drawing attention from patients, doctors and the pharmaceutical industry.
European Medicines AgencyRasonqueEuropean Commission
Rank over time, top of the chart is #1. 20 snapshots from 4 d ago to 3 d ago.
Evidence
- EMA recommends authorisation of Rasonque for metastatic pancreatic cancer · European Medicines Agency (EMA)
API: https://socialmediatrends-api.osmike.com/v1/trends/2364347